Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 19/20 | 0.73 |
| ▸ | PPARA | Q07869 | 19/20 | 0.73 |
| ▸ | PPARD | Q03181 | 15/20 | 0.73 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5015790 | 0.94 | PPARG (0.83) | PPARGPPARAPPARD | |
| SCHEMBL5017607 | 0.91 | PPARG (0.75) | PPARGPPARAPPARD | |
| SCHEMBL5017281 | 0.90 | PPARG (0.89) | PPARGPPARAPPARD | |
| SCHEMBL5017731 | 0.88 | PPARG (0.73) | PPARGPPARAPPARD | |
| SCHEMBL5015847 | 0.87 | PPARG (0.71) | PPARGPPARAPPARD | |
| SCHEMBL5015839 | 0.85 | PPARG (0.69) | PPARGPPARAPPARD | |
| SCHEMBL5015717 | 0.85 | PPARG (0.74) | PPARGPPARAPPARD | |
| SCHEMBL5015733 | 0.84 | PPARG (1.00) | PPARGPPARAPPARD | |
| SCHEMBL5015834 | 0.84 | PPARG (0.86) | PPARGPPARAPPARD | |
| SCHEMBL5022675 | 0.84 | PPARG (0.72) | PPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1567523-B1 | INDOLYL DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-08-20 | — | — | EP | disclosed |
| US-7098228-B2 | e.g., 3-{1-[2-(3,5-Dimethoxy-phenyl)-5-methyl-oxazol-4-ylmethyl]-1H-indol-4-yl}-2-ethoxy-propionic acid ethyl ester; treating non-insulin dependent diabetes mellitus; PPAR receptor activation | HOFFMANN-LA ROCHE INC. (US) | 2006-08-29 | — | — | US | disclosed |
| EP-1567523-A1 | INDOLYL DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004048371-A1 | INDOLYL DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2004-06-10 | — | — | WO | disclosed |
| US-20040106657-A1 | Indolyl derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106657-A1 | Indolyl derivatives | GPR119, IRS1, INSR | PPARG 354/4885PPARA 286/4885PPARD 207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.